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OBJECTIVE — Wolfram syndrome is an autosomal recessive neurodegenerative disorder
characterized by diabetes insipidus, diabetes (nonautoimmune), optic atrophy, and deafness (a
set of conditions referred to as DIDMOAD). The WFS1 gene is located on the short arm of
chromosome4.Wolframsyndromeprevalenceis1in770,000livebirths,witha1in354carrier
frequency.
RESEARCH DESIGN AND METHODS — We evaluated six Italian children from ﬁve
unrelatedfamilies.GeneticanalysisforWolframsyndromewasperformedbyPCRampliﬁcation
and direct sequencing.
RESULTS — Mutation screening revealed ﬁve distinct variants, one novel mutation
(c.1346CT; p.T449I) and four previously described, all located in exon 8.
CONCLUSIONS — Phenotype-genotype correlation is difﬁcult, and the same mutation
gives very different phenotypes. Severely inactivating mutations result in a more severe pheno-
type than mildly inactivating ones. Clinical follow-up showed the progressive syndrome’s
seriousness.
Diabetes Care 31:1743–1745, 2008
W
olfram syndrome includes non-
autoimmune diabetes and optic
atrophy within the ﬁrst decade
followed by diabetes insipidus and deaf-
ness (1). Additional characteristics are
ureterohydronephrosis, neuropsychiatric
and endocrinological impairment, and,
seldomly,powderedcataractandretinop-
athy (2). Mortality is 65% before age 35
years, due to central respiratory and renal
failure(1).Thegeneinvolved(WFS1)was
identiﬁedin1998onchromosome4p(3).
WFS1 spans 33.4 kb of genomic DNA
and includes eight exons: the ﬁrst is non-
coding, 2–7 are coding, and the 8th is 2.6
kb long (3). WFS1 mRNA encodes an
890–amino acid polypeptide with nine
putative transmembrane domains and a
100-kd molecular mass. WFS1 mRNA is
expressed in heart, brain, placenta, lung,
and pancreas; WFS1 transcripts were
detected in liver, skeletal muscle, and
kidney. Wolframin protein is an endogly-
cosidaseH-sensitivemembraneglycopro-
tein that localizes in the endoplasmic
reticulum. In the endoplasmic reticulum,
it regulates membrane trafﬁcking and
protein processing and has a crucial role
in -cell death through the apoptotic
pathway (4).
RESEARCH DESIGN AND
METHODS— We evaluated six Ital-
ian patients (two male and four female)
with Wolfram syndrome from ﬁve differ-
ent families. We performed brain nuclear
magnetic resonance (to assess posterior
pituitary and brain structures) (5), endo-
crinologic evaluation, ultrasonography,
and intravenous urography (to detect re-
nal abnormalities) (6).
Genomic DNA for WFS1 gene muta-
tion screening was obtained after written
informedconsent.TheWFS1genecoding
regionwasanalyzedbyPCRampliﬁcation
and direct sequencing using primers and
methods previously described (7). Se-
quences were compared with human
genomic and cDNA WSF1 sequences
(GenBank accession no. AF084481), and
changes in the nucleotides were checked
against published polymorphisms and
mutations. Each sequence alteration was
conﬁrmed by sequencing both DNA
strands of two independent PCR products.
RESULTS— Mutation screening re-
vealed a total of ﬁve distinct variants, in-
cluding one novel mutation (c.1346CT;
p.T449I) and four previously described
variants (c.1230_1233delCTCT, c.1362_
1377del16, c.1328GT, and IVS6 
16GA). Two patients (case 1, a male pa-
tientwithacompoundheterozygousmuta-
tion [S443I]  [IVS6  16GA], and case
2, a female patient carrying a homozygous
mutation c.1362_1377del16) have already
been the subjects of publication by our
group(8).Allthemutationswereinexon8.
Case 3, a male patient with homozy-
gous mutation at the nucleotide
c.1362_1377del16, showed the most se-
vere phenotype, and at age 11 years he
experienced acute respiratory failure.
Brain nuclear magnetic resonance re-
vealed brain stem, cerebellum, medulla,
and pons atrophy (Fig. 1A) and reduced
high-signal intensity from the posterior
pituitary and optic nerve (Fig. 1B). Uri-
nary tract infections were followed by
kidney insufﬁciency. Renal scintigraphy
showed left-obstructive hydronephrosis
at the pyelo-uretheral junction. Urody-
namic study showed high bladder pres-
sure and conﬁrmed hydronephrosis.
Atonic bladder with emptying problems
was followed by radical cystectomy with
ileal duct when the subject was 19 years
old. Interestingly, the other patient carry-
ing the same mutation did not show any
respiratory involvement up to now. Her
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kidneyinsufﬁciency,andshedidnototh-
erwise require surgery. The other de-
scribed male patient ([S443I]  [IVS6 
16GA])showedalessseverephenotype
characterized only by diabetes and optic
atrophy and without diabetes insipidus
or kidney damage. The female patient
homozygous for mutation c.1230_
1233delCTCT leading to V412fsX440,
case 4, showed all the clinical features of
the syndrome.
In family no. 5, a new mutation,
c1346CT (ACCATC codon change),
leadingtopT449Iaminoacidchange,was
detected; it was heterozygous in consan-
guineous parents. Cases 5 and 6 were sis-
ters(mutationc.1346CT;p.T449I),but
they still possessed a different phenotype:
the older had urethral involvement and
severe anorexia; the younger had mi-
croalbuminuria but no neurological or
urinary tract involvement.
CONCLUSIONS — Severe respira-
tory complications (the “severe pheno-
type”) (9) were observed in one boy. A
severe respiratory involvement led to the
diagnosis of Wolfram syndrome in an
adult patient (10). Neurological dysfunc-
tions are responsible for apneic and hy-
popneic spells during sleep.
Urinary tract involvement including
hydrourether, detrursor-sphincter dys-
synergia, and detrursor overactivity oc-
curs in up to 90% of patients in
adolescence or adulthood and might be
duetoneuronaldegeneration(6).Nocor-
relationhasbeenfoundbetweentheblad-
der dysfunction and presence or duration
of other manifestations, suggesting that
bladder dysfunction may be a primary
rather than a secondary manifestation of
the syndrome (6).
Mutational studies in patients with
Wolframsyndromereportedawidespec-
trumofmutationsdistributedthroughout
the coding sequence of the WFS1 gene.
WFS1 protein in vivo is organized as a
tetramer that originates a membrane
Ca
2 channel of the endoplasmic reticu-
lum, and lack of function of WFS1 deter-
mines apoptotic input signaling (11). In
spite of the great improvements in the
studyofthephysiologicalroleofWFS1,
it is still difﬁcult to establish a pheno-
type-genotype correlation (9). WFS1
expressionwasdetectedinbothpancre-
atic -cells and the limbic system of
mice. Moreover, using immunohisto-
chemical methods, strong WFS1 ex-
Figure 1—Brain magnetic resonance of case 3. Upper panel: brain stem atrophy. Lower panel:
optic nerve atrophy.
Genetic mechanisms of Wolfram syndrome
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andcerebellumofmice.Usingaspeciﬁc
rat insulinoma cell line and fractionated
mouse brain tissue, wolframin localiza-
tion into the endoplasmic reticulum
was conﬁrmed.
The only predicting information that
genetic analysis can give regards the dif-
ference between severely inactivating
(such as premature stop codon from in-
sertion or deletion) and mildly inactivat-
ing mutations (such as missense
mutations). Patients homozygous for a
missense mutation seem to have a better
prognosis than patients carrying a se-
verely inactivating mutation. Even in our
study, although clinical symptoms are
different, patients showing more severe
features had a severely inactivating muta-
tion (9).
All the mutations described are lo-
cated in exon 8, corresponding to the
transmembraneregionandcarboxytailof
wolframin protein (9). This is in agree-
ment with other studies in Italian and
worldwide populations. Phenotype-
genotype correlation is difﬁcult: the same
mutation gives different phenotypes in
both related and unrelated subjects. Se-
verelyinactivatingmutationsseemtogive
a more severe phenotype than mildly in-
activating mutations.
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